171 related articles for article (PubMed ID: 7587960)
1. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
[TBL] [Abstract][Full Text] [Related]
4. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
[TBL] [Abstract][Full Text] [Related]
5. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.
Abelö A; Eriksson UG; Karlsson MO; Larsson H; Gabrielsson J
J Pharmacol Exp Ther; 2000 Nov; 295(2):662-9. PubMed ID: 11046103
[TBL] [Abstract][Full Text] [Related]
6. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
8. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
9. [Effect of proton pump inhibitors (PPIs) on wound healing of gastric mucosal cell injury].
Masaoka T; Suzuki H; Ishii H
Nihon Rinsho; 2004 Mar; 62(3):556-60. PubMed ID: 15038103
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
11. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
12. Lansoprazole: a comprehensive review.
Zimmermann AE; Katona BG
Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole and ethanol metabolism: comparison with omeprazole and cimetidine.
Battiston L; Tulissi P; Moretti M; Pozzato G
Pharmacol Toxicol; 1997 Dec; 81(6):247-52. PubMed ID: 9444664
[TBL] [Abstract][Full Text] [Related]
14. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
15. Current status of acid pump antagonists (reversible PPIs).
Wurst W; Hartmann M
Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase.
Suzuki H; Masaoka T; Minegishi Y; Motosugi Y; Miura S; Ishii H
Wound Repair Regen; 2004; 12(1):93-9. PubMed ID: 14974970
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole: pharmacokinetics and pharmacodynamics.
Moules IK
Br J Clin Pract Suppl; 1994; 75():41-5; discussion 46-7. PubMed ID: 8060801
[No Abstract] [Full Text] [Related]
18. Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats.
Endo H; Yoshida H; Ohmi N; Higuchi S
Antimicrob Agents Chemother; 2001 Dec; 45(12):3451-5. PubMed ID: 11709323
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
Puchalski TA; Krzyzanski W; Blum RA; Jusko WJ
J Clin Pharmacol; 2001 Mar; 41(3):251-8. PubMed ID: 11269565
[TBL] [Abstract][Full Text] [Related]
20. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
Kinoshita M; Saito N; Noto T; Tamaki H
J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]